Ligand Pharmaceuticals Inc. (LGND) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Ligand Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Thank you. Operator instructions Your first question comes from Derek Jellinek. Derek Jellinek – Susquehanna Financial Group Great. Thanks for taking my question, guys. A couple questions. On 4665, can you maybe talk about the current ongoing trial in ITP, the enrollment that is?...

  Earnings calls 2008-08-25

  Tags: Ligand Pharmaceuticals Inc.

• Ligand Pharmaceuticals Incorporated Q1 2008 Earnings Call Transcript

  Question-and-Answer Session Operator Operator instructions Your first question comes from the line of David Webber with Broadpoint Capital. David Webber – Broadpoint Capital Thank you. Couple questions, first just to clarify the projection of $20 million in royalties, is that from AVINZA alone or is...

  Earnings calls 2008-05-20

  Tags: Ligand Pharmaceuticals Inc.

• Ligand Pharmaceuticals Q4 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of David Webber with Broadpoint Capital. David Webber - Broadpoint Capital Hi. Just a couple of questions, John. First, I don't know if you have this information or not, but can you tell us whether the PROMACTA NDA...

  Earnings calls 2008-02-20

  Tags: Ligand Pharmaceuticals Inc.

Additional Resources

• Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights

  Acquisition Would Result in Well Capitalized Company with Robust Royalty Assets and Broad Research Pipeline Conference Call Today at 5:30 p.m. Eastern SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a definitive merger agreement to acquire Pharmacopeia (NASDAQ: PCOP),...

  Articles 2008-09-24

• Beacon Equity Issues Technical Trade Alerts on Market Movers: GSAE, THMD, AKSN, LGND, CRAY, DAL

  DALLAS, Sept. 17 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m Today's Trade Alerts include: Green Star Alternative Energy Inc. (Pink Sheets: GSAE), Thermadyne Holdings...

  Articles 2008-09-17

• Ligand Pharmaceuticals Appoints Dr. Stephen Sabba to Board of Directors

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that Stephen L. Sabba, M.D., age 49, has been elected to Ligand's Board of Directors, effective immediately. Dr. Sabba takes the Board seat previously held by Elizabeth M. Greetham, who served as a Director from March 2007 and resigned from the...

  Articles 2008-08-04

• BeaconEquity.com Issues Trade Alerts on Market Movers: WEL, LGND, PPCO, KIDS, GNLK, VCSY

  DALLAS, Aug. 4 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m Today's Trade Alerts include: Boots & Coots International Well Control Inc. , Ligand Pharmaceuticals...

  Articles 2008-08-04

• Ligand Pharmaceuticals Announces Second Quarter Results

  Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced financial results for the three and six months ended June 30, 2008 and provided an update on key programs. Second Quarter Results Total revenues from...

  Articles 2008-07-31

• Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA® NDA

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that the U.S. Food and Drug Administration has extended the priority review period for GlaxoSmithKline's GSK New Drug Application NDA for PROMACTA[R] eltrombopag for the short-term treatment of chronic idiopathic thrombocytopenic purpura ITP. The Prescription Drug User Fee...

  Articles 2008-06-20

• CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc

  Combined Company to Drive Stockholder Value with Commitment to Molecular Chaperone Technology Platform and Near-Term Commercialization Opportunities in Oncology Acquisition Subject to Customary Closing Conditions Including Innovive Stockholder Approval Company to Host Conference Call at 9:00 AM EDT (6:00 AM PDT) Today to...

  Articles 2008-06-09

• Ligand to Present at the Needham & Company Biotechnology and Medical Technology Conference on June 11

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that President and Chief Executive Officer John L. Higgins and Dr. Martin Meglasson, Vice President of Discovery Research, will be presenting at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008, at...

  Articles 2008-06-04

• New Analyst Reports for SMURFIT STONE CONTAINER CORPORATION, INFOSYS TECHNOLOGIES LIMITED, COSTCO WHOLESALE CORP, and LIGAND PHARMACEUTICALS INCORPORATED

  Free Analyst Review MaybachFinancial.com is one of the fastest growing independent and unbiasedresearch firms in the world. Through our numerous partnerships with many ofthe top investment minds in the world, we provide research on companiesmaking a move in the markets. Investors seeking genuine analyst opinions ontheir investments for SMURFIT STONE...

  Articles 2008-05-28

• Mergent, Inc. Announces Changes to the HealthShares™ Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction

  NEW YORK, May 15 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the following changes effective on the opening of trading on Monday May 19, 2008: Genzyme Corporation will replace LifeCell Corp. ...

  Articles 2008-05-15

• Mergent, Inc. Announces Changes to the HealthShares™ Composite Index, HealthShares™ Dermatology and Wound Care Index and HealthShares™ Orthopedic Repair Index

  NEW YORK, May 14 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the following changes with effect from the opening of trade on Monday May 19, 2008: Genzyme Corporation will replace LifeCell Corp....

  Articles 2008-05-14

• Ligand Pharmaceuticals Announces First Quarter Results

  Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced financial results for the first quarter of 2008, and provided an operating forecast and program updates. Financial Results Total revenues from continuing operations for the three...

  Articles 2008-05-01

• Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has initiated a Phase II study of its small-molecule thrombopoietin TPO mimetic, LGD-4665. The 24 patient, double-blind placebo-controlled trial is designed to evaluate the safety and efficacy of LGD-4665 in adult patients with idiopathic thrombocytopenic purpura ITP over...

  Articles 2008-04-24

• Ligand to Hold First Quarter Results Conference Call on May 1

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it plans to report first quarter 2008 financial results on Thursday, May 1, 2008, following the close of market. Ligand's President and CEO, John L. Higgins and Vice President of Finance and CFO, John P. Sharp will...

  Articles 2008-04-21

• Ligand Partner GlaxoSmithKline Receives FDA Acceptance and Granted Priority Review for PROMACTA® NDA

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that the U.S. Food and Drug Administration FDA has accepted for filing and review GlaxoSmithKline's new drug application NDA and has granted a priority review status for PROMACTA([R]) eltrombopag for treatment of chronic short-term idiopathic thrombocytopenic purpura ITP. Priority review is...

  Articles 2008-03-03

• Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results

  Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced financial results for the three and 12 months ended December 31, 2007, and reviewed business highlights of the fourth quarter of 2007 and early 2008. Financial Results ...

  Articles 2008-02-20

• Ligand to Hold Fourth Quarter Results Conference Call on February 20

  SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it plans to report fourth quarter 2007 financial results on Wednesday, February 20, 2008 following the close of market. Ligand's President and CEO, John L. Higgins, Vice President of Finance and CFO, John P. Sharp and Vice President of...

  Articles 2008-02-12